All Sauce from Weekly Sauce:

The GLP-1 drug semaglutide can help obese people manage debilitating knee arthritis, a new trial has found. People who received weekly injections of semaglutide — the active agent in the diabetes drug Ozempic and the weight-loss medication Wegovy — had a nearly 14% decrease in their body weight after 68 weeks, compared with 3% of…  read on >  read on >

Hillary Fisher thinks receiving weight-loss surgery as a teenager put her on the path to a better life. Fisher is one of 260 teens who participated in a long-term study which recently concluded that weight-loss surgery can bring lasting health benefits for obese teenagers. “It changed my life,” Fisher, now 31, said in a news…  read on >  read on >

A new guidance issued jointly by groups representing U.S. surgeons, anesthesiologists and gastroenterologists affirms that most people taking popular GLP-1 weight-loss meds can keep taking them in the weeks before a surgery. Concerns had arisen because the drugs, which include semaglutide (Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound), liraglutide (Saxenda) and dulaglutide (Trulicity), can…  read on >  read on >